-
1Academic Journal
Συγγραφείς: L. P. Ananieva
Πηγή: Научно-практическая ревматология, Vol 58, Iss 5, Pp 520-531 (2020)
Θεματικοί όροι: системная склеродермия, интерстициальные пневмонии, 03 medical and health sciences, 0302 clinical medicine, RC925-935, иммуносупрессанты, ритуксимаб, антифиброзные препараты, Diseases of the musculoskeletal system, тоцилизумаб, 3. Good health
Σύνδεσμος πρόσβασης: https://rsp.mediar-press.net/rsp/article/download/2955/2029
https://doaj.org/article/736bf8562a7b4fdaa68815500512b928
https://cyberleninka.ru/article/n/sovremennaya-terapiya-interstitsialnyh-pnevmoniy-assotsiirovannyh-s-sistemnoy-sklerodermiey
https://rsp.mediar-press.net/rsp/article/view/2955/2029
https://rsp.mediar-press.net/rsp/article/download/2955/2029 -
2Academic Journal
Συγγραφείς: I. B. Medvedev, E. V. Samodurova, S. V. Svetlichnaya, L. V. Batalina, N. N. Dergacheva, И. Б. Медведев, Е. В. Самодурова, С. В. Светличная, Л. В. Баталина, Н. Н. Дергачёва
Πηγή: Ophthalmology in Russia; Том 20, № 2 (2023); 208-214 ; Офтальмология; Том 20, № 2 (2023); 208-214 ; 2500-0845 ; 1816-5095 ; 10.18008/1816-5095-2023-2
Θεματικοί όροι: ИЛ-23, immuno-inflammatory diseases, genetically engineered biological drugs, immunosuppressants, corticosteroids, biological modulators of the immune response, tumor necrosis factor-α, IL-6, IL-17, IL-23, иммуновоспалительные заболевания, генно-инженерные биологические препараты, иммуносупрессанты, кортикостероиды, биологические модуляторы иммунного ответа, фактор некроза опухоли-α, ИЛ-6, ИЛ-17
Περιγραφή αρχείου: application/pdf
Relation: https://www.ophthalmojournal.com/opht/article/view/2098/1091; Foster CS, Vitale AT. Diagnosis and Treatment of Uveitis. 2nd Edition. New Delhi: Jaypee Brothers Medical Publishers; 2013.; Давыдова ГА, Лисицына ТА, Ковалева ЛА, Сорожкина ЕС, Зайцева АА, Байсангурова АА. Клинические вариации увеитов при иммуновоспалительных заболеваниях. Обзор литературы. Часть 1. Офтальмология. 2022;19(3):465–474. doi:10.18008/1816-5095-2022-3-465-474.; Tsirouki T, Dastiridou A, Symeonidis Ch, Tounakaki O, Brazitikou I, Kalogeropoulos Ch, Androudi S. A Focus on the Epidemiology of Uveitis, Ocular Immunology and Inflammation, 2018;26(1):2 –16. doi:10.1080/09273948.2016.1196713.; Давыдова Г.А., Лисицына Т.А., Ковалева Л.А., Сорожкина Е.С., Зайцева А.А., Байсангурова А.А. Клинические вариации увеитов при иммуновоспалительных заболеваниях. Обзор литературы. Часть 2. Офтальмология. 2022;19(4):719–726. doi:10.18008/1816-5095-2022-4-719-726G.; Арбеньева НС, Чехова ТА, Братко ВИ, Обухова ОО, Горбенко ОМ, Шваюк АП, Повещенко ОВ, Трунов АН, Черных ВВ. Влияние комплексного лечения с использованием тромбоцитарной аутоплазмы на клинико-лабораторные показатели пациентов с эндогенным увеитом и макулярным отеком. Сибирский научный медицинский журнал. 2019;39(5):110–118. doi:10.15372/SSMJ20190513.; Cаlamia KT, Wilson FC, Icen M, Crowson CS, Gabriel SE, Kremers HM. Epidemiology and clinical characteristics of Beccet’s disease in the US: a populationbased study. Arthritis Rheum. 2009;61(5):600–604. doi:10.1002/art.24423.; Галушко ЕА, Насонов ЕЛ. Распространенность ревматических заболеваний в России. Альманах клинической медицины. 2018;46(1):32–39. doi:10.18786/2072-0505-2018-46-1-32-39.; Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005 Sep;140(3):509–516. doi:10.1016/j.ajo.2005.03.057.; Denniston A, Barry R, Nguyen Q, Lee R, Murray P. Pharmacotherapy for uveitis: current management and emerging therapy. Clin Ophthalmol. 2014;8:1891–1911. doi:10.2147/opth.s47778.; Garcia-Montoya L, Gul H, Emery P. Recent advances in ankylosing spondylitis: understanding the disease and management. F1000Res. 2018 Sep 21;7:F1000 Faculty Rev-1512. PMID: 30345001; PMCID: PMC6173104. doi:10.12688/f1000research.14956.1.; Hansen IS, Schoonejans JM, Sritharan L, van Burgsteden JA, Ambarus CA, Baeten DLP, den Dunnen J. ER stress abrogates the immunosuppressive effect of IL-10 on human macrophages through inhibition of STAT3 activation. Inflamm Res. 2019 Sep;68(9):775–785. Epub 2019 Jun 21. PMID: 31227842; PMCID: PMC6667425. doi:10.1007/s00011-019-01261-9.; Rademacher J, Poddubnyy D, Pleyer U. Uveitis in spondyloarthritis. Ther Adv Musculoskelet Dis. 2020 Sep 12;12:1759720X20951733. doi:10.1177/1759720X20951733. PMID: 32963592; PMCID: PMC7488890.; Дроздова ЕА. Вопросы классификации и эпидемиологии увеитов. Клиническая офтальмология: РМЖ. 2016;3:155–159. doi:10.21689/2311-7729-2016-16-3-155-159.; Давыдова Г.А., Лисицына Т.А., Ковалева Л.А., Сорожкина Е.С., Зайцева А.А., Байсангурова. А.А. Клинические вариации увеитов при иммуновоспалительных заболеваниях. Обзор литературы. Часть 1. Офтальмология. 2022;19(3):465–474. doi:10.18008/1816-5095-2022-3-465-474.; Cantini F, Nannini C, Cassara E, Kaloudi O, Niccoli L. Uveitis in Spondyloarthritis: An Overview. J Rheumatol Suppl. 2015 Nov;93:27-9. doi:10.3899/jrheum.150630.; Lee JH, Choi M, Rim THT, Lee SC, Lee CS. Clinical Characteristics and Prognostic Factors in Ankylosing Spondylitis Associated Uveitis. Ocul Immunol Inflamm. 2019;27(1):64–69. doi:10.1080/09273948.2017.1359630. Epub 2017 Oct 11. PMID: 29020487.; Balasubramaniam B, Chong YJ, Azzopardi M, Logeswaran A, Denniston AK. Topical Anti-Inflammatory Agents for Non-Infectious Uveitis: Current Treatment and Perspectives. J Inflamm Res. 2022 Nov 28;15:6439–6451. doi:10.2147/JIR.S288294. PMID: 36467992; PMCID: PMC9717596.; Rosenbaum JT, Bodaghi B, Couto C, Zierhut M, Acharya N, Pavesio C, Tay-Kearney M-L, Neri P, Douglas K, Pathai S, Song AP, Kron M, Foster CS. New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review. Seminars in Arthritis and Rheumatism. 2019;49(3):438–445. SSN 0049-0172. doi:10.1016/j.semarthrit.2019.06.004.; Valdes LM, Sobrin L. Uveitis Therapy: The Corticosteroid Options. Drugs. 2020;80:765–773. doi:10.1007/s40265-020-01314-y.; Арбеньева НС, Чехова ТА, Братко ВИ, Трунов АН, Черных ВВ. Оценка эффективности комплексного лечения неинфекционных увеитов, сопровождающихся макулярным отеком. Современные технологии в офтальмологии. 2018;3:199–202.; Крахмалева ДА, Пивин ЕА, Труфанов СВ, Маложен СА. Современные тенденции в лечении увеитов. Офтальмология. 2017;14(2):113–119. doi:10.18008/1816-5095-2017-2-113-119.; Hunter RH, Lobo A-M. Dexamethasone intravitreal implant for the treatment of noninfectious uveitis. Clinical Ophthalmology. 2011;5:1613–1621.; Лебедев ОИ, Суров АВ, Матненко ТЮ, Салихов ММ. Иммунотерапия увеитов, ассоциированных с системными заболеваниями. РМЖ. Клиническая офтальмология 2013;13(2):69–71.; The Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Louis TA, Sugar EA, Thorne JE. Randomized Comparison of Systemic Anti-inflammatory Therapy Versus Fluocinolone Acetonide Implant for Intermediate, Posterior and Panuveitis: The Multicenter Uveitis Steroid Treatment Trial. Ophthalmology. 2011 October;118(10):1916–1926. doi:10.1016/j.ophtha.2011.07.027.; Jaffe GJ, McCallum RM, Branchaud B, Skalak C, Butuner Z, Ashton P. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology. 2005 Jul;112(7):1192–1198. doi:10.1016/j.ophtha.2005.03.013.; Tirelli F, Zannin ME, Vittadello F, Agnolucci J, Mazzarolo M, Zulian F. Methotrexate Monotherapy in Juvenile Idiopathic Arthritis Associated Uveitis: Myth or Reality? Ocular Immunology and Inflammation. 2022 Oct-Nov;30(7-8):1763-1767. doi:10.1080/09273948.2021.1951303.; Smith WM. Cyclosporine: A Historical Perspective on Its Role in the Treatment of Noninfectious Uveitis. Journal of Ocular Pharmacology and Therapeutics. 2017;5:247–262. doi:10.1089/jop.2016.0155.; Дроздова ЕА. Иммуносупрессивная терапия неинфекционных увеитов и ретиноваскулитов. Офтальмология. 2012;9(2):58–61. doi:10.18008/1816-5095-2012-2-58-61.; Лисицына ТА, Давыдова ГА, Алекберова ЗС, Голоева РГ, Катаргина ЛА, Насонов ЕЛ. Сравнительная эффективность различных схем иммуносупрессивной терапии увеита у пациентов с болезнью Бехчета. Научно-практическая ревматология. 2021;59(2):173–183. doi:10.47360/1995-4484-2021-173-183.; Duica I, Voinea LM, Mitulescu C, Istrate S, Coman IC, Ciuluvica R. The use of biologic therapies in uveitis. Rom J Ophthalmol. 2018 Apr-Jun;62(2):105–113. PMID: 30206553; PMCID: PMC6117529.; Sharma SM, Damato E, Hinchcliffe AE, Andrews CD, Myint K, Lee R, Dick AD. Long-term efficacy and tolerability of TNFα inhibitors in the treatment of noninfectious ocular inflammation: an 8-year prospective surveillance study. Br J Ophthalmol. 2021 Sep;105(9):1256–1262. doi:10.1136/bjophthalmol-2018-312767. Epub 2019 Mar 12. PMID: 30862619; PMCID: PMC8380906.; Van Bentum RE, Heslinga SC, Nurmohamed MT, Gerards AH, Griep EN, Koehorst CBJM, Kok MR, Schilder AM, Verhoef M, van der Horst-Bruinsma IE. Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab — The GO-EASY Study. J Rheumatol. 2019 Feb;46(2):153–159. doi:10.3899/jrheum.180312. Epub 2018 Nov 1. PMID: 30385705.; Arepalli S, Rosenbaum JT. The use of biologics for uveitis associated with spondyloarthritis. Curr Opin Rheumatol. 2019 Jul;31(4):349–354. doi:10.1097/BOR.0000000000000619. PMID: 31107288.; van der Horst-Bruinsma IE, Robinson PC, Favalli EG, Verbraak FD, Kim M, Kumke T, Bauer L, Hoepken B, Deodhar A. Certolizumab Pegol Treatment in Patients with Axial-Spondyloarthritis-Associated Acute Anterior Uveitis: a Narrative Review. Rheumatol Ther. 2022 Dec;9(6):1481–1497. doi:10.1007/s40744-022-00486-1. Epub 2022 Sep 30. PMID: 36178585; PMCID: PMC9562975.; Leclercq M, Desbois AC, Domont F, Maalouf G, Touhami S, Cacoub P, Bodaghi B, Saadoun D. Biotherapies in Uveitis. J Clin Med. 2020 Nov 8;9(11):3599. doi:10.3390/jcm9113599. PMID: 33171664; PMCID: PMC7695328.; Mesquida M, Molins B, Llorenc V, Hernandez MV, Espinosa G, Sainz de la Maza M, Adan A. Twenty-four month follow-up of tocilizumab therapy for refractory uveitis-related macular edema. Retina. 2018;38(7):1361–1370. doi:10.1097/IAE.0000000000001690.; Maccora I, Abu Rumeileh S, Curci F, de Libero C, Marrani E, Mastrolia MV, Pagnini I, Simonini G. Tocilizumab and Abatacept for the Treatment of Childhood Chronic Uveitis: A Monocentric Comparison Experience. Front Pediatr. 2022 Apr 12;10:851453. doi:10.3389/fped.2022.851453. PMID: 35498797; PMCID: PMC9039300.; Deodhar AA, Miceli-Richard C, Baraliakos X, Marzo-Ortega H, Gladman DD, Blanco R, Das Gupta A, Martin R, Safi J Jr, Porter B, Shete A, Rosenbaum JT. Incidence of uveitis in secukinumab‐treated patients with ankylosing spondylitis: pooled data analysis from three phase 3 studies. ACR open rheumatology. 2020;2(5):294–299. doi:10.1002/acr2.11139; Lasave AF, You C, Ma L, Abusamra K, Lamba N, Valdes Navarro M, Meese H, Foster CS. Long-term outcomes of rituximab therapy in patients with noninfectious posterior uveitis refractory to conventional immunosuppressive therapy. Retina. 2018;38(2):395–402. doi:10.1097/IAE.0000000000001563.; https://www.ophthalmojournal.com/opht/article/view/2098
-
3Academic Journal
Πηγή: University Therapeutic Journal, Vol 3, Iss 1 (2021)
Θεματικοί όροι: болезнь Крона, диагностика, лечение, 5-аминосалициловая кислота, глюкокортикостероиды, иммуносупрессанты, Medicine
Περιγραφή αρχείου: electronic resource
Relation: http://ojs3.gpmu.org/index.php/Un-ther-journal/article/view/2605; https://doaj.org/toc/2713-1912; https://doaj.org/toc/2713-1920
Σύνδεσμος πρόσβασης: https://doaj.org/article/27e5266745d24bf5a159e400ad889802
-
4Academic Journal
Πηγή: University Therapeutic Journal, Vol 3, Iss 1 (2021)
Θεματικοί όροι: язвенный колит, диагностика, лечение, 5-аминосалициловая кислота, глюкокортикостероиды, иммуносупрессанты, Medicine
Περιγραφή αρχείου: electronic resource
Relation: http://ojs3.gpmu.org/index.php/Un-ther-journal/article/view/2604; https://doaj.org/toc/2713-1912; https://doaj.org/toc/2713-1920
Σύνδεσμος πρόσβασης: https://doaj.org/article/4c89efd786454d54a145d513c965ac50
-
5Academic Journal
Πηγή: University Therapeutic Journal, Vol 3, Iss 1 (2021)
Θεματικοί όροι: иммуносупрессанты, болезнь Крона, диагностика, глюкокортикостероиды, Medicine, лечение, 5-аминосалициловая кислота
Σύνδεσμος πρόσβασης: https://doaj.org/article/27e5266745d24bf5a159e400ad889802
-
6Academic Journal
Πηγή: University Therapeutic Journal, Vol 3, Iss 1 (2021)
Θεματικοί όροι: иммуносупрессанты, диагностика, глюкокортикостероиды, Medicine, язвенный колит, лечение, 5-аминосалициловая кислота
Σύνδεσμος πρόσβασης: https://doaj.org/article/4c89efd786454d54a145d513c965ac50
-
7Academic Journal
Συγγραφείς: I. T. Murkamilov, I. S. Sabirov, V. V. Fomin, Zh. A. Murkamilova, И. Т. Муркамилов, И. С. Сабиров, В. В. Фомин, Ж. А. Муркамилова
Πηγή: The Russian Archives of Internal Medicine; Том 10, № 1 (2020); 38-46 ; Архивъ внутренней медицины; Том 10, № 1 (2020); 38-46 ; 2411-6564 ; 2226-6704 ; 10.20514/2226-6704-2020-10-1
Θεματικοί όροι: моноклональные антитела, glomerulonephritis, nephrotic syndrome, immunosuppressants, monoclonal antibodies, гломерулонефрит, нефротический синдром, иммуносупрессанты
Περιγραφή αρχείου: application/pdf
Relation: https://www.medarhive.ru/jour/article/view/998/872; https://www.medarhive.ru/jour/article/view/998/882; Saleem M.A. Molecular stratification of idiopathic nephrotic syndrome. Nat Rev Nephrol. 2019; 15: 750–765. DOI:10.1038/s41581-019-0217-5; Чеботарева Н.В., Бобкова И.Н., Непринцева Н.В. и др. Мочевые биомаркеры повреждения подоцитов: значение для оценки течения и прогноза хронического гломерулонефрита. Терапевтический архив. 2015; 6(87): 34-39. DOI:10.17116/terarkh201587634-39; Смирнов А.В. Лечение гломерулопатий циклоспорином: правильный подход с неверным обоснованием. Нефрология. 2010; 14(4): 9-22. DOI:https://doi.org/10.24884/1561-6274-201014-4-9-22; Beaudreuil S., Lorenzo H.K., Elias M. et al. Optimal management of primary focal segmental glomerulosclerosis in adults. Int J Nephrol Renovasc Dis. 2017; 10: 97–107. Published 2017 May 10. DOI:10.2147/IJNRD.S126844; Бобкова И.Н., Козловская Л.В., Цыгин А.Н. и др. Клинические рекомендации по диагностике и лечению фокальносегментарного гломерулосклероза. Нефрология. 2015; 19(1): 78-85. DOI:https://doi.org/10.24884/1561-6274-201519-1-56-61; Chashmniam S., Kalantari S., Nafar M., & Boroumandnia N. The Metabolomics Signature Associated with Responsiveness to Steroid Therapy in Focal Segmental Glomerulosclerosis: A Pilot Study. Revista de Investigación Clínica. 2019; 71: 2: 106-115. DOI:10.24875/RIC.18002668; Li M., Alfieri C.M., Morello W. et al. Assessment of increased glomerular permeability associated with recurrent focal segmental glomerulosclerosis using an in vitro model of the glomerular filtration barrier. Journal of Nephrology. 2019; 1-9. DOI:10.1007/s40620-01900683-2; Мельник А.А. Фокально-сегментарный гломерулосклероз: генетический анализ и целевая терапия. Почки. 2018; 7(1): 35-49. DOI:10.22141/2307-1257.7.1.2018.122218.; Feng D., DuMontier C., Pollak M.R. Mechanical challenges and cytoskeletal impairments in focal segmental glomerulosclerosis. American Journal of Physiology-Renal Physiology. 2018; 314: 5: F921-F925. DOI:https://doi.org/10.1152/ajprenal.00641.2017; Lu C.C., Wang G.H., Lu J. et al. Role of podocyte injury in glomerulosclerosis. Renal Fibrosis: Mechanisms and Therapies. Springer, Singapore. 2019; 195-232. DOI:https://doi.org/10.1007/978-981-13-8871-2_10; Wharram B.L., Goyal M., Wiggins J.E. et al. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor ransgene. J Am Soc Nephrol. 2005; 16(10): 2941-52. DOI:10.1681/ASN.2005010055; Hildebrandt F. Genetic kidney diseases. Lancet. 2010; 10: 375(9722): 1287-1295. DOI:10.1016/S0140-6736(10)60236-X; Игнатова М.С., Длин В.В. Нефротический синдром: прошлое, настоящее и будущее. Рос вестн перинатол и педиатр 2017; 62:(6): 29–44. DOI:10.21508/1027–4065–2017–62–6–29–44; Sánchez de la Nieta M.D., Arias L.F., de la Torre M. et al. Familial focal and segmentary hyalinosis. Nefrologia. 2003;23(2):172-6. PMID: 12778884. [in Spanish]; Shalhoub R.J. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. The Lancet. 1974; 304: 7880: 556-560. DOI:https://doi.org/10.1016/S0140-6736(74)91880-7; Батюшин М.М., Гадаборшева Х.З., Сарвилина И.В. и др. Взаимосвязь MCP-1 и тубулоинтерстициального фиброза при хроническом гломерулонефрите. Нефрология. 2017; 21(5): 22-27. DOI: https://doi.org/10.24884/1561-6274-2017-21-5-19-24; Чеботарева Н.В., Бобкова И.Н., Козловская Л.В. и др. Оценка дисфункции подоцитов по степени нефринурии при протеинурических формах хронического гломерулонефрита. Терапевтический архив. 2011; 6(83): 18-23; Yu D., Petermann A., Kunter U. et al. Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. Journal of the American Society of Nephrology. 2005; 16: 6: 17331741. DOI:10.1681/ASN.2005020159; Löwik M.M., Groenen P.J., Levtchenko E.N. et al. Molecular genetic analysis of podocyte genes in focal segmental glomerulosclerosis a review. European journal of pediatrics. 2009; 168: 11: 1291. DOI:https://doi.org/10.1007/s00431-009-1017-x; D’Agati V.D., Kaskel F.J., Falk R.J. Focal segmental glomerulosclerosis. New England Journal of Medicine. 2011; 365: 25:2398-2411. DOI:10.1056/NEJMra1106556; Shankland S.J. The podocyte’s response to injury: role in proteinuria and glomerulosclerosis. Kidney international. 2006; 69: 12:2131-2147. DOI:https://doi.org/10.1038/sj.ki.5000410; D’Agati V., Fogo A., Bruijn J., Jennette J.C. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis. 2004; 43(2): 368-382. PMID: 14750104. DOI:10.1053/j.ajkd.2003.10.024; Самусева Е.С. Первичный фокальный сегментарный гломерулосклероз (ФСГС): проблемы патоморфологической диагностики. Український журнал нефрології та діалізу. 2011; 2(30): 52-60; Kambham N., Markowitz G.S., Valeri A.M. et al. Obesity-related glomerulopathy: an emerging epidemic Kidney Int. 2001; 59: 4: 14981509. DOI:https://doi.org/10.1046/j.1523-1755.2001.0590041498.x; Stokes M.B., Valeri A.M., Markowitz G.S., & D’Agati V.D. Cellular focal segmental glomerulosclerosis: clinical and pathologic features. Kidney international. 2006; 70: 10: 1783-1792. DOI: https://doi.org/10.1038/sj.ki.5001903; D’Agati V. The many masks of focal segmental glomerulosclerosis. Kidney international. 1994; 46: 4: 1223-1241. DOI:https://doi.org/10.1038/ki.1994.388; Weiss M.A., Daquioag E., Margolin E.G., Pollak V.E. Nephrotic syndrome, progressive irreversible renal failure, and glomerular «collapse»: A new clinicopathologic entity? American Journal of Kidney Diseases. 1986; 7: 1: 20-28. DOI:https://doi.org/10.1016/S0272-6386(86)80052-X; Fogo A.B., Lusco M.A., Najafian B., Alpers C.E. AJKD Atlas of Renal Pathology: focal segmental glomerulosclerosis. American Journal of Kidney Diseases. 2015; 66: 2: e1-e2. DOI: https://doi.org/10.1053/j.ajkd.2015.04.007; Nili F., Saboori F., Jahanzad I., Mehrazma M. Electron microscopic findings suggestive of focal and segmental glomerulosclerosis in patients with steroid-resistant nephrotic syndrome. Ultrastructural pathology. 2019; 43: 1: 6-12. DOI:https://doi.org/10.1080/01913123.2019.1584258; Thomas D.B., Franceschini N., Hogan S.L. et al. Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney international. 2006; 69: 5: 920-926. DOI:https://doi.org/10.1038/sj.ki.5000160; De Zeeuw D., Remuzzi G., Parving H.H. et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney international. 2004; 65: 6: 2309-2320. DOI:10.1111/j.1523-1755.2004.00653.x; Kunz R., Friedrich C., Wolbers M., Mann J.F. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the reninangiotensin system on proteinuria in renal disease. Annals of internal medicine. 2008; 148: 1: 30-48. DOI:10.7326/0003-4819-148-1200801010-00190; Samuel S., Bitzan M., Zappitelli M. et al. Canadian Society of Nephrology Commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis: management of nephrotic syndrome in children. American Journal of Kidney Diseases. 2014; 63: 3: 354-362; Ныркова П.А., Савенкова Н.Д. Исследования эффективности цитостатической терапии часто рецидивирующего, гормонозависимого и со стероидной токсичностью нефротического синдрома у детей. Нефрология. 2015; 19(1): 30-40; Савенкова Н.Д, Папаян А.В. Нефротический синдром в практике педиатра. С-Пб., Эскулап. 1999; 256 с.; Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol. 2005; 5(6): 472-484. DOI:10.1038/nri1632; Козловская Л.В. Хронический гломерулонефрит: аргументы в пользу применения циклоспорина.Клиническая нефрология. 2010; 3: 56-61; Козловская Л.В. Фокально-сегментарный гломерулосклероз: фокус на циклоспорин. Клиническая нефрология. 2010; 5: 23-28; Cattran D.C., Appel G.B., Hebert L.A. et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int. 1999; 56(6): 2220-2226. DOI:10.1046/j.15231755.1999.00778.x.; Niaudet P., Habib R. Cyclosporine in the treatment of idiopathic nephrosis. J Am Soc Nephrol. 1994; 5(4): 1049-1056. PMID: 7849244; Chapter 6: Idiopathic focal segmental glomerulosclerosis in adults. Kidney Int Suppl. (2011); 2012 Jun; 2(2): 181-185. DOI:10.1038/kisup.2012.19; Shen X., Jiang H., Ying M. et al. Calcineurin inhibitors cyclosporin A and tacrolimus protect against podocyte injury induced by puromycin aminonucleoside in rodent models. Scientific reports. 2016; 6: 32087. DOI:10.1038/srep32087; Klaassen I., Özgören B., Sadowski C.E. et al. Response to cyclosporine in steroid-resistant nephrotic syndrome: discontinuation is possible. Pediatric nephrology. 2015; 30: 9: 1477-1483. DOI:10.1007/s00467015-3109-3; Giglio S., Provenzano A., Mazzinghi B. et al. Heterogeneous genetic alterations in sporadic nephrotic syndrome associate with resistance to immunosuppression. Journal of the American Society of Nephrology. 2015; 26: 1: 230-236. DOI: https://doi.org/10.1681/ASN.2013111155; Fu Y.F., Liu G.l. Mycophenolate Mofetil Therapy for children with lupus nephritis refractory to both intravenous cyclophosphomide and cyclosporine. Clin Nephrol. 2001; 55(4): 318–321. PMID: 11334319; Ulinski T., Ranchin B., Said M-H. Switch from cyclosporine A (CyA) to mycophenolate mofetil improves kidney function in children with nephrotic syndrome and CyA- induced nephrotoxicity. Nephrology Dialis Transplantation. 2003; 18(Suppl 4): 261; Gulati S., Pokhariyal S., Sharma R.K. et al. Pulse cyclophosphamide therapy in frequently relapsing nephrotic syndrome. Nephrol Dial Transplant. 2001; 16(10): 2013–2017. PMID: 11572890; Nakagawa T., Shiratori A., Kawaba Y. et al. Efficacy of rituximab therapy against intractable steroid-resistant nephrotic syndrome. Pediatrics International. 2016; 58: 10: 1003-1008. DOI: https://doi.org/10.1111/ped.12948; Kamei K., Okada M., Sato M. et al. Rituximab treatment combined with methylprednisolone pulse therapy and immunosuppressants for childhood steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2014; 29(7): 1181–1187. DOI:10.1007/s00467-014-2765-z; Wang C.S., Liverman R.S., Garro R. et al. Ofatumumab for the treatment of childhood nephrotic syndrome. Pediatr Nephrol. 2017; 32(5): 835–841. DOI:10.1007/s00467-017-3621-8; Ravani P., Bonanni A., Ghiggeri G.M. Randomised controlled trial comparing ofatumumab to rituximab in children with steroiddependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol. BMJ Open. 2017; 7: e013319. DOI:10.1136/bmjopen-2016-013319; Solomon S., Zolotnitskaya A., Del Rio M. Ofatumumab in posttransplantation recurrence of focal segmental glomerulosclerosis in a child. Pediatric transplantation. 2019; С. e13413. DOI:https://doi.org/10.1111/petr.13413; https://www.medarhive.ru/jour/article/view/998
-
8Academic Journal
Συγγραφείς: M. S. Ignatova, V. V. Dlin, М. С. Игнатова, В. В. Длин
Πηγή: Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics); Том 62, № 6 (2017); 29-44 ; Российский вестник перинатологии и педиатрии; Том 62, № 6 (2017); 29-44 ; 2500-2228 ; 1027-4065 ; 10.21508/1027-4065-2017-62-6
Θεματικοί όροι: моноклональные антитела, nephrotic syndrome, congenital and infantile nephrotic syndrome, selective immunosuppressants, monoclonal antibodies, нефротический синдром, врожденный и инфантильный нефротический синдром, селективные иммуносупрессанты
Περιγραφή αρχείου: application/pdf
Relation: https://www.ped-perinatology.ru/jour/article/view/588/572; Игнатова М.С., Шатохина О.В. Диагностика и лечение нефротического синдрома у детей. Руководство для врачей, М: МИА 2009; 288. [Ignatova M.S., Shatokhina O.V. Diagnosis and treatment of nephrotic syndrome in children. A guide for physicians, M: MIA, 2009; 288. (in Russ)]; Clark A.G., Barratt T.M. Steroid-responsive nephrotic syndrome. In: Pediatr Nephrology. T.M. Barratt, E.D. Avner, W.E. Harmon (eds), 4th ed. Lippincott, Williams and Wilkins, Baltimore, 1999; 731–747.; Wong W. Idiopathic nephrotic syndrome in New Zealand children, demographic, clinical features, initial management and outcome after twelve-month follow-up: results of a threeyear national surveillance study. J Paediatr Child Health 2007; 3: 337–341. DOI:10.1111/j.1440-1754.2007.01077.x; Цыгин А.Н. Нефротический синдром. В кн.: Детская нефрология. Под ред. Э. Лойманна, А.Н. Цыгина, А.А. Саркисяна. М: Изд. «Литерра» 2010; 123–140. [Tsygin A.N. Nephrotic syndrome. In: Children’s Nephrology. E. Lojmann, A.N. Zygin, A.A. Sarkisyan (eds). M: “Literra” 2010; 123–140. (in Russ)]; Серов В.В., Варшавский В.А. Что называть гломерулонефритом: спорные вопросы классификации. Архив патологии 1987; 1: 67–82. [Serov V.V., Varshavsky V.A. What is called glomerulonephritis: a controversial classification issues. Аrkhiv patologii 1987; 1: 67–82. (in Russ)]; Broyer M., Meyrier A., Niaudet P, Habib R. Мinimal changes and focal segmental glomerular sclerosis. Oxford textbook of clinical nephrology, 2-nd ed. A. Davison, S. Cameron, J-P. Grunftld (eds). Oxford, New-York, Tokio: Oxford medical press, 1998; 493–523.; Cameron S. Historical perspective. In: The Nephrotic syndrome. S. Cameron, R. Glassock, M. Dekker (eds). New York, Basel, 1988; 3–56.; Матвеев М.П. Нефротический синдром у детей. М, 1975; 25. [Matveev M.P. Nephrotic syndrome in children. Moscow, 1975; 25. (in Russ)]; Rheault M., Gbadegesin R. The Genetics of Nephrotic Syndrome. J Pediatr Genet 2016; 5 (1): 15–24. DOI:10.1055/s0035-1557109; Jalanko H. Pathogenesis of proteinuria: lessons learned from nephrin and podocin. Pediatr Nephrol 2003; 18: 487–491.; Kaplan J.M., Kim S.H., North K.N., Rennke H., Correia L.A., Tong H.Q. et al. Mutation in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genetic 2000; 24: 251–256.; Wang J.-J., Mao J.-H. The etiology of congenital nephrotic syndrome: current status and challenges. World J Pediatr 2016; 12 (2): 149–158. DOI:10.1007/s12519-016-0009-y.; Hallman N., Hjelt L., Abvenainen E.K. Nephrotic syndrome in newborn and young infants. Ann Pediatr Fenn 1956; 2: 227–241.; Kestila M., Lenkkeri U., Mannikko M. Positionally cloned gene for a njval glomerular protein – nephrinis mutated in congenital nephritic syndrome. Mol Cell 1998; 1: 575–582.; Fuchshuber A., Niaudet P., Gribouval O., Jean G., Gubler M.C., Broyer M., Antignac C. Congenital nephrotic syndrome of the Finnish type: linkage to the locus in a non-Finnish population. Pediatr Nephrol 1996; 10: 135138.; Patrakka J., Kestila M., Wartovaara J., Ruotsalainen V., Tissari P., Lenkkeri U. et al. Congenital nephrotic syndrome (NPHS1): Feature resulting from different mutation in Finnish patients. Kidney Int 2000; 58:972–980.; Vats A., Costello B., Mauer M. Glomerular structural factors in progression of congenital nephrоtic syndrome. Pediatr Nephrol 2003; 18: 234–240.; Prikhodina L., Poltavets N., Galeeva N., Zaklyazminskaya E., Dlin V. Podocin gene (NPHS2) mutations in children with sporadic steroid-resistant nephrоtic syndrome. Pediatr Nephrol 2007; 22 (9): 1486.; Schwarz K., Simons M., Reiser J., Saleem M.A., Faul C., Kriz W. et al. Podocin, a raft-associated component of glomerular slit diaphragm, interacts with CD2AP and nephrin. J Clin Invest 2001; 108: 1621–1629. DOI:10.1172/JCI12849; Huber T.B., Simons M., Hartleben B., Sernetz L., Schmidts M., Gundlach E. et al. Molecular basis of the functional podocinnephrin complex: mutation in the NPHS2 gene disrupt nephrin targeting to the lipid raft microdomains. Hum Mol Genet 2003; 12:3397–3405. DOI:10.1093/hmg/ddg360; Pereira A.C., Pereira AB., Mota G.F., Cunha R.S., Herkenhoff F.L., Pollak M.R. et al. NPHS2 R229Q functional variant is associated with microalbuminuria in the general population. Kidney Int 2004; 65:1026–1030. DOI:10.1111/j.15231755.2004.00479.x; Caridi G., Bertelli R., Carrea A. Prevalence, genetics, and clinical features of patients carring podocin mutations in steroidresistant nonfamilial focal segmental glomeruloscerosis. J Am Soc Nephrol 2001; 12: 2742–2746.; Ruf R.G., Lichtenberger A., Karle S.M., Haas J.P., Anacleto F.E., Schultheiss M. et al. Patients with mutation in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 2004; 15: 722–732.; Koziell A., Grech V., Hussain S., Lee G., Lenkkeri U., Tryggvason K., Scambler P. Genotype/phenotype correlations of NPHS1 and NPHS2 mutations in nephrotic syndrome advocate a functional inter-relationship in glomerular filtration. Hum Mol Genet 2002; 11: 379–388.; Pohl M., Bhatnagar V., Mendoza S.A., Nigam S.K. Toward an etiological classification of developmental disorders of the kidney and upper urinary tract. Kidney Int 2002; 61: 10–19.; Шатохина О.В., Игнатова М.С., Османов И.М. Клинический полиморфизм и генетическая характеристика синдромов Дениса–Драша и Фрайзера. Нефрология и диализ 2004; 6: 337–343. [Shatokhina O.V., Ignatova M.S., Osmanov I.M. Clinical polymorphism and genetic characteristics of syndromes Denys-Drash and Fraiser. Nefrologiya i dializ 2004; 6: 337–343. (in Russ)]; Ruf R., Schultheiss M., Lichtenbrger A., Karle S.M., Zalewski I., Mucha B. et al. Prevalence of WT1 mutation in a large cohort of patients with steroid-resistant and steroid-sensitive nephrоtic syndrome. Kidney Int 2004; 66: 564–570.; Schumacher V., Scharer K., Wubl E., Altrogge H., Bonzel K.E., Guschmann M. et al. Spectrum of early onset nephrоtic syndrome associated with WT1 missence mutations. Kidney Int 1998; 53: 1594–1600.; Lahdenkari A-T., Kestila M., Holmberg Ch. Nephrin gene (NPHS1) in patients with minimal change nephrotic syndrome (MCNS). Kidney Int 2004; 65: 1856–1863.; Cao Q., Li GM., Xu H. Coenzyme Q (10) treatment for one child with COQ6 gene mutation induced nephrotic syndrome and literature review. Zhonghua Er Ke Za Zhi 2017; 55 (2): 135–138. DOI:10.3760/cma.j.issn.0578-1310.2017.02.016.; Длин В.В., Асратян А.А., Рейзис А.Р. Частота маркеров НВ-вирусной инфекции у больных с нефротическим синдромом. Педиатрия 1991; 7: 24–27. [Dlin V.V., Asratyan A.A., Reyzis A.R. Frequency of markers of HB virus infection in patients with nephrotic syndrome. Pediatriya 1991; 7: 24–27. (in Russ)]; Длин В.В., Чумакова О.В. Принципы терапии гломерулонефрита, ассоцированного с гепатит Ви гепатит С-вирусной инфекцией у детей. Педиатрическая фармакотерапия 2003; 1 (2): 65–68. [Dlin V.V., Chumakova O.V. Principles of treatment of glomerulonephritis, associate with hepatitis Вand hepatitis C-viral infection in children. Pediatricheskaya farmakoterapiya 2003; 1 (2): 65–68. (in Russ)]; Игнатова М.С. Моя жизнь и развитие нефрологии детского возраста в России. M, 2016; 64. [Ignatova M.S. My life and the development of pediatric Nephrology in Russia. Moscow, 2016; 64. (in Russ)]; Arneil G. Management of the nephrotic syndrome in the child. In Clinical Pediatric Nephrology. E. Lieberman (ed.). Toronto, 1976; 146–180.; Игнатова М.С., Вельтищев Ю.Е. Болезни почек у детей. М: Изд-во «Медицина» 1973; 308. [Ignatova M.S., Veltishhev Yu.E. Kidney Disease in children. M: Publishing house “Meditsina” 1973; 308. (in Russ)]; Игнатова М.С., Вельтищев Ю.Е. Детская нефрология. Руководство для врачей. Л: Медицина 1982; 528. [Ignatova M.S., Veltischev Yu.E. Pediatric Nephrology. Guide for physicians. L: Meditsina 1982; 528. (in Russ)]; ISKDC: The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr 1981; 98: 561–564.; Bouissou F., Pjlcoux J., Lenoup M. Epidemiology of idiopatic nephrotic syndrome. Pediatr Nephrol 1993; 7: 25–28.; Наумова В.И., Ситникова В.П. Гломерулонефрит. В кн.: Болезни почек в детском возрасте. Под ред. М.Я. Студеникина. М: Медицина 1976; 102–124. [Naumova V.I., Sitnikova V.P. Glomerulonephritis. In: Kidney disease in children. M.Ya. Studenikin (ed.). Moscow: Meditsina 1976; 102–124. (in Russ)]; Foster B., Shults J., Zemel B., Leonard M. Risk factors for glucocorticoid – induced obesity in children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 2006; 21: 973–980. DOI:10.1007/s00467-006-0100-z; Игнатова М.С., Вельтищев Ю.Е. Детская нефрология. Руководство для врачей. Л: Медицина 1989; 455. [Ignatova M.S., Veltischev Yu.E. Pediatric Nephrology. Guide for physicians. L: Meditsina 1989; 455. (in Russ)]; Папиж С.В., Фокеева Е.В., Ружицкая Е.А. Применение иммуномодулирующего препарата левамизола в лечении гормонозависимого и часторецидивирующего нефротического синдрома при первичном гломерулонефрите у детей. Нефрология и диализ 2004; 6 (1): 58–61. [Papizh S.V., Fokeeva E.V., Ruozyckaya E.A. The use of immunomodulating drug levamisole in the treatment of hormone-dependent and frequently relapsing nephrotic syndrome in primary glomerulonephritis in children. Nefrologiya i dializ 2004; 6 (1): 58–61. (in Russ)]; Martinelli R., Okumura A.S., Pereira L.J., Rocha H. Primary focal segmental glomerulosclerosis in children: prognostic factors. Pediatr Nephrol 2001; 16: 656–661.; Игнатова М.С., Москалева Е.С., Харина Е.А. Алгоритм лечения нефротического синдрома при первичном гломерулонефрите у детей. Пособие для врачей. М, 2001; 24. [Ignatova M.S., Moskaleva E.S., Kharina E.A. An algorithm for the treatment of nephrotic syndrome in primary glomerulonephritis in children. A manual for physicians. Moscow, 2001; 24. (in Russ)]; Borel J.F. Mechanism of action of cyclosporine A & rationale for use in nephrotic syndrome. Clin Nephrol 1991; 5: 23–30.; Epting Th., Hartmann K., Sandqvist A., Nitschke R., Gordjani N. Cyclosporin A stimulates apical Na+/H+ exchange in LLCPK1/PKE20 proximal tubular cells. Pediatr Nephrol 2006; 21: 939–946. DOI:10.1007/s00467-006-0097-3; Meyrier A. Treatment of glomerular disease with cyclosporine A. Nephrol Dial Transpl 1989; 4: 123–131.; Niaudet P., Broyer M. Cyclosporine in the therapy of idiopathic nephrotic syndrome in children. In: International Year book of nephrology. V.E. Andreucci (ed.). Dordrecht.: Kluwer Academic, 1989; 155–168.; Игнатова М.С., Харина Е.А., Курбанова Э.Г. Эффективность Сандиммун-Неорала при нефротическом синдроме у детей России и Казахстана, по данным многоцентрового контролируемого исследования. Педиатрия 2001; 6: 90–94. [Ignatova M.S., Kharina E.A., Kurbanova E.G. The efficacy of Sandimmun-Neoral nephrotic syndrome in children of Russia and Kazakhstan, according to a multicenter controlled study. Pediatriya 2001; 6: 90–94. (in Russ)]; Eugui E.M., Amquist S.J., Miller C.D., Allison A.C. Lymphocytoselective citostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991; 33: 161–173.; Senda M., DeLustro B., Eugui E., Natsumeda Y. Mycophenolatic acid, an ingibitor of IMP dehydrogenase that is also on immunosuppressive agent, suppresses the cytocine-induced nitric acid production in mouse and rat vascular endothelial cells. Transplantation 1995; 60: 1143–1148.; Fu Y.F., Liu G.l. Mycophenolate Mofetil Therapy for children with lupus nephritis refractory to both intravenous cyclophosphomide and cyclosporine. Clin Nephrol 2001; 55: 318–321.; Ulinski T., Ranchin B., Said M-H. Switch from cyclosporine A (CyA) to mycophenolate mofetil improves kidney function in children with nephrotic syndrome and CyAinduced nephrotoxicity. Nephrology Dialis Transplantation 2003; 18 (Suppl 4): 261.; Матвеева М.В., Зробок О.И., Вашурина Т.В., Мазо А.М., Дмитриенко С.В., Леонова Л.В., Цыгин А.Н. Оценка эффективности такролимуса у детей с нефротическим синдромом, рефрактерным к терапии циклоспорином А. Педиатрия 2014; 93 (2): 81–85. [Matveeva M.V., Zrobok O.I., Vashurina T.V., Mazo А.M., Dmitrienko S.V., Leonova L.V., Tsygin А.N. Evaluation of the effectiveness of tacrolimus in children with nephrotic syndrome refractory to therapy with cyclosporine A. Pediatriya 2014; 93 (2): 81–85. (in Russ)]; Вашурина Т.В., Зробок О.И., Комарова О.В. Применение ритуксимаба при стероид-зависимом нефротическом синдроме у детей. Нефрология и диализ 2016; 18 (1): 50–61. [Vashurina T.V., Ztrobok O.I., Komarova O.V. The use of rituximab for steroid-dependent nephrotic syndrome in children. Nefrologiya i dializ 2016; 18 (1): 50–61. (in Russ)]; Nakagawa T., Shiratori A., Kawaba Y., Kanda K., Tanaka R. Efficacy of rituximab therapy against intractable steroid-resistant nephrotic syndrome. Pediatr Int 2016; 58 (10): 1003– 1008. DOI:10.1111/ped.12948; Kamei K., Okada M., Sato M., Fujimaru T., Ogura M., Nakayama M. et al. Rituximab treatment combined with methylprednisolone pulse therapy and immunosuppressants for childhood steroid-resistant nephrotic syndrome. Pediatr Nephrol 2014; 29 (7): 1181–1187. DOI:10.1007/s00467014-2765-z; Wang C.S., Liverman R.S., Garro R., George R.P., Glumova A., Karp A. et al. Ofatumumab for the treatment of childhood nephrotic syndrome. Pediatr Nephrol 2017; 32 (5): 835–841. DOI:10.1007/s00467-017-3621-8
-
9Academic Journal
Συγγραφείς: A. O. Golovenko, O. V. Golovenko, А. О. Головенко, О. В. Головенко
Πηγή: Meditsinskiy sovet = Medical Council; № 14 (2018); 44-49 ; Медицинский Совет; № 14 (2018); 44-49 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2018-14
Θεματικοί όροι: иммуносупрессанты, therapy, vedolizumab, immunosuppressants, терапия, ведолизумаб
Περιγραφή αρχείου: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/2650/2612; Allez M, Karmiris K, Louis E, Van Assche G, BenHorin S, Klein A et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis, 2010, 4(4): 355-66.; Pereira R, Faria R, Lago P, Torres T. Infection and Malignancy Risk in Patients Treated with TNF Inhibitors for Immune-Mediated Inflammatory Diseases. Curr Drug Saf, 2017, 12(3): 162-170.; Pérez-De-Lis M, Retamozo S, Flores-Chávez A, Kostov B, Perez-Alvarez R, Brito-Zerón P et al. Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Expert Opin Drug Saf, 2017, 16(11): 1255-1271.; Katsanos AH, Katsanos KH. Inflammatory bowel disease and demyelination: more than just a coincidence? Expert Rev Clin Immunol, 2014, 10(3): 363-73.; Harbord M, Eliakim К, Bettenworth В, Karmiris К, Katsanos К, Kopylov U et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J Crohns Colitis, 2017, 11(7): 769–784.; Gomollón F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay J et al. Third European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis, 2017, 11(7): 3–25.; Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn’s Disease in Adults. Am J Gastroenterol, 2018, 113(4): 481-517.; Ивашкин В.Т., Шелыгин Ю.А., Халиф И.Л., Белоусова Е.А., Шифрин О.С., Абдулганиева Д.И. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению болезни Крона. Колопроктология, 2017, 2(60): 7-29.; Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med, 2005, 353: 375–381.; Chen Y, Bord E, Tompkins T, Miller J, Tan CS, Kinkel RP et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med, 2009, 361: 1067–1074.; Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med, 2013, 369: 699–710.; Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med, 2013, 369: 711–721.; Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology, 2014, 147: 618–627.; Wang MC, Zhang LY, Han W, Shao Y, Chen M, Ni R et al. PRISMA–efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore), 2014, 93(28): e326.; Loftus EV, Colombel JF, Feagan BG, Vermeire S, Sandborn WJ, Sands BE et al. Long-term Efficacy of Vedolizumab for Ulcerative Colitis. J Crohns Colitis, 2017, 1, 11(4): 400-411.; Vermeire S, Loftus EV, Colombel JF, Feagan BG, Sandborn WJ, Sands BE et al. Long-term Efficacy of Vedolizumab for Crohn’s Disease. J Crohns Colitis, 2017, 1, 11(4): 412-424.; Noman M, Ferrante M, Bisschops R, De Hertogh G, Van den Broeck K, Rans K et al. Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn’s Disease and Ulcerative Colitis. J Crohns Colitis, 2017, 1, 11(9): 1085-1089.; Ha C, Ullman TA, Siegel CA, Kornbluth A. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol, 2012, 10(9): 1002-1007.; Amiot A, Grimaud JC, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X et al. Observatory on Efficacy and of Vedolizumab in Patients With Inflammatory Bowel Disease Study Group; Groupe d’Etude Therapeutique des Affections Inflammatoires du tube Digestif. Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol, 2016, 14(11): 1593- 1601.; Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X et al. OBSERV-IBD study group and the GETAID. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther, 2017, 46(3): 310-321.; Eriksson C, Marsal J, Bergemalm D, Vigren L, Björk J, Eberhardson M et al. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). Scand J Gastroenterol, 2017, 52(6-7): 722-729.; Baumgart DC, Bokemeyer B, Drabik A, Stallmach A, Schreiber S. Vedolizumab Germany Consortium. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice–a nationwide consecutive German cohort study. Aliment Pharmacol Ther, 2016, 43(10): 1090-1102.; Dulai PS, Singh S, Jiang X, Peerani F, Narula N, Chaudrey K et al. The Real-World Effectiveness and Safety of Vedolizumab for ModerateSevere Crohn’s Disease: Results From the US VICTORY Consortium. Am J Gastroenterol, 2016, 111(8): 1147-55.; Kopylov U, Ron Y, Avni-Biron I, Koslowsky B, Waterman M, Daher S et al. Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli RealWorld Experience. Inflamm Bowel Dis, 2017, 23(3): 404-408.; Shelton E, Allegretti JR, Stevens B, Lucci M, Khalili H, Nguyen DD. Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort. Inflamm Bowel Dis, 2015, 21(12): 2879-85.; Macaluso FS, Orlando R, Fries W, Scolaro M, Magnano A, Pluchino D et al. The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases. Dig Liver Dis, 2018, 50(7): 675-681.; Allegretti JR, Barnes EL, Stevens B, Storm M, Ananthakrishnan A, Yajnik V et al. Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab. Dig Dis Sci, 2017, 62(6): 1590- 1596.; Stallmach A, Langbein C, Atreya R, Bruns T, Dignass A, Ende K et al. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease — a prospective multicenter observational study. Aliment Pharmacol Ther, 2016, 44(11-12): 1199- 1212.; Vivio EE, Kanuri N, Gilbertsen JJ, Monroe K, Dey N, Chen CH et al. Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice. J Crohns Colitis, 2016, 10(4): 402-409.; Samaan MA, Pavlidis P, Johnston E, Warner B, Digby-Bell J, Koumoutsos I et al. Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres. Frontline Gastroenterol, 2017, 8(3): 196-202.; Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D’Haens G et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut, 2017, 66(5): 839-851.; Rahier JF, Magro F, Abreu C, Armuzzi A, BenHorin S, Chowers Y et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis, 2014, 8(6): 443-68.; Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol, 2014, 76(6): 802-12.; Bye WA, Jairath V, Travis SPL. Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease. Aliment Pharmacol Ther, 2017, 46(1): 3-15.; Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol, 2001, 33(4): 289- 94.; Ивашкин В.Т., Шелыгин Ю.А., Абдулганиева Д.И. и соавт. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению язвенного колита. Колопроктология, 2017, 1(59): 6–30.; Yajnik V, Khan N, Dubinsky M, Axler J, James A, Abhyankar B et al. Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age. Adv Ther, 2017, 34: 542–59.; Navaneethan U, Edminister T, Zhu X, Kommaraju K, Glover S. Vedolizumab Is Safe and Effective in Elderly Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis, 2017, 23: E17.; Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J Crohn’s Colitis, 2017, 11(7): 769–784.; Feagan B, Lasch K, Lissoos T, Cao C, Wojtowicz A et al. Rapid response to vedolizumab therapy in biologic-naïve patients with inflammatory bowel diseases. J Clin Gastroenterol, 2018; doi. org/10.1016/j.cgh.2018.05.026 .; Feagan B, Rubin D, Danese S, Vermeire S, Abhyankar B, Sankoh S et al. Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists. J Clin Gastroenterol, 2017;15: 229–239.; Vedolizumab as induction and maintenance therapy for Crohn’s disease in patients naive to or who have failed tumor necrosis factor antagonist therapy. Inflam Bowel Dis, 2017; 23: 97–106; Faleck D, Shashi P, Meserve J, Rahal M, Kadire S, Tran G, et al. Comparative effectiveness of vedolizumab and TNF-antagonist therapy in ulcerative colitis: a multicentre consortium propensity score-matched analysis. J Crohn’s Colitis, 2018, 12: S019.; Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med, 2010, 15;362(15): 1383-95.; Gouynou C, Peyrin-Biroulet L. Letter: addition of methotrexate neither restores clinical response nor improves the pharmacokinetic profile of vedolizumab-treated patients. Aliment Pharmacol Ther, 2017, 46: 1019–1020.; Peyrin-Biroulet L, Danese S, Argollo M, Pouillon L, Peppas S, Gonzalez-Lorenzo M et al. Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn’s Disease or Ulcerative Colitis: a Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol, 2018, Jun 20.
-
10Academic Journal
Συγγραφείς: D. A. Krakhmaleva, E. A. Pivin, S. V. Trufanov, S. A. Malozhen, Д. А. Крахмалева, Е. А. Пивин, С. В. Труфанов, С. А. Маложен
Πηγή: Ophthalmology in Russia; Том 14, № 2 (2017); 113-119 ; Офтальмология; Том 14, № 2 (2017); 113-119 ; 2500-0845 ; 1816-5095 ; 10.18008/1816-5095-2017-2
Θεματικοί όροι: плазмаферез, immunosuppressants, corticosteroids, biological modulators of the immune response, tumor necrosis factor-α, VEGF inhibitors, plasmapheresis, иммуносупрессанты, кортикостероиды, биологические модуляторы иммунного ответа, фактор некроза опухоли-α, ингибиторы VEGF
Περιγραφή αρχείου: application/pdf
Relation: https://www.ophthalmojournal.com/opht/article/view/371/365; Rupesh V Agrawal, Somasheila Murthy, Virender Sangwan, and Jyotirmay Biswas. Current approach in diagnosis and management of anterior uveitis. Indian J Ophthalmol. 2010;58(1):11–19. doi:10.4103/0301‑4738.58468.; Denniston A, Barry R, Nguyen Q, Lee R, Murray P. Pharmacotherapy for uveitis: current management and emerging therapy. Clin Ophthalmol. 2014;8:1891‑1911. doi:10.2147/opth.s47778.; Miserocchi E, Fogliato G, Modorati G, Bandello F. Review on the worldwide epidemiology of uveitis. Eur J Ophthalmol. 2013;23(5):705–717. DOI:10.5301/ejo.; Cimino L, Aldigeri R, Salvarani C, et al. The causes of uveitis in a referral centre of Northern Italy. Int Ophthalmol. 2010;30(5):521–529. doi:10.1007/s10792‑010‑9359‑y.; Streilein J. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol. 2003;3(11):879–889. doi:10.1038/nri1224.; Papotto, P.H.; Marengo, E.B.; Sardinha, L.R.; Goldberg, A.C.; Rizzo, L.V. Immunotherapeutic strategies in autoimmune uveitis. Autoimmun. Rev. 2014,13:909–916. doi:10.1016/j.autrev.2014.05.003; Mérida S, Palacios E, Navea A, Bosch‑Morell F. Macrophages and Uveitis in Experimental Animal Models. Mediators of Inflammation. 2015;2015:1–10. doi:10.1155/2015/671417.; Lee, R.W.; Nicholson, L.B.; Sen, H.N.; Chan, C.C.; Wei. L.; Nussenblatt, R.B.; Dick, A.D. Autoimmune and autoinflammatory mechanisms in uveitis. Semin. Immunopathol. 2014;36:581–594. doi:10.1007/s00281‑014‑0433‑9.; Takase, H., Futagami, Y., Yoshida, T., Kamoi, K., Sugita, S., Imai, Y., Mochizuki, M. Cytokine profile in aqueous humor and sera of patients with infectious or noninfectious uveitis. Investig. Ophthalmol. Vis. Sci. 2006;47:1557–1561.; Velichko V., Lebedev V.V., Katargina L.A., Slepova O.S [Clinical and immunological study the new pathogenetic remedy for children endogenous uveitis treatment]. Kliniko‑immunologicheskoe issledovanie novogo sredstva patogeneticheskoy terapii endogennykh uveitov u detey. [Allergologie and immunology in pediatrics]. Allergologiya i immunologiya v pediatrii. 2008;3(14):31–37. (in Russ.).; Rodriguez A, Calonge M, Pedroza‑Seres M, et al. Referral patterns of uveitis in a tertiary eye care center. Arch Ophthalmol. 1996;114(5):593–599.; Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005 Sep;140(3):509–16.; McClellan K. A., Coster D. J. Uveitis: a strategy for diagnosis. Australian and New Zealand Journal of Ophthalmologv 1987;15:227–24.; Intraocular Inflammation, Uveitis. Clinical & Experimental Ophthalmology. 2008;36:A282‑A304. doi:10.1111/j.1442‑9071.2008.01751.x.; L.K. Moshetova, A.P. Nesterov, E.A. Egorov. [Ophthalmology. Clinical recommendations. Scientific‑practical publication]. M:GEOTAR‑Media; 2007.(in Russ.).; Happe W. [Ophthalmology.Practitioners Handbook]. M.:MedPress; 2005. (in Russ.).; Senchenko N.Ya., Shchuko A.G, Malyshev V.V. [Uveitis: manual]. M:GEOTAR‑Media;2010 (in Russ.).; Zaytseva N.S., Katsnel'son L.A. [Uveitis]. M.Medicina; 1984 (in Russ.).; Deschenes J, Murray P, Rao N, Nussenblatt R. International Uveitis Study Group (IUSG) Clinical Classification of Uveitis. Ocular Immunology and Inflammation. 2008;16(1‑2):1‑2. doi:10.1080/09273940801899822.; Tempest‑Roe S, Joshi L, Dick A, Taylor S. Local therapies for inflammatory eye disease in translation: past, present and future. BMC Ophthalmology. 2013;13(1). doi:10.1186/1471‑2415‑13‑39.; Durrani K, Zakka FR, Ahmed M, Memon M, Siddique SS, Foster CS. Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease. Surv Ophthalmol. 2011;56(6): 474–510. doi:10.1016/j.survophthal.2011.05.003.; S S. Pujari, , J H. Kempen, , CW. Newcomb, S Gangaputra, E Daniel, E B. Suhler, J E. Thorne, DA. Jabs, GA. Levy‑Clarke, R B. Nussenblatt, J T.Rosenbaum, C. S Foster. Cyclophosphamide for ocular inflammatory diseases. Ophthalmology. 2010;117(2):356. doi:10.1016/j.ophtha.2009.06.060.; Rebecca S Hunter, Ann‑Marie Lobo. Dexamethasone intravitreal implant for the treatment of noninfectious uveitis. Clinical Ophthalmology. 2011;5:1613–1621.; The Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, John H. Kempen, Michael M. Altaweel, Janet T. Holbrook, Douglas A. Jabs, Thomas A. Louis, Elizabeth A. Sugar, Jennifer E.Thorne. Randomized Comparison of Systemic Anti‑inflammatory Therapy Versus Fluocinolone Acetonide Implant for Intermediate, Posterior and Panuveitis: The Multicenter Uveitis Steroid Treatment Trial. Ophthalmology. 2011 October; 118(10):1916–1926. doi:10.1016/j.ophtha.2011.07.027; Kiernan DMieler W. The use of intraocular corticosteroids. Expert Opinion on Pharmacotherapy. 2009;10(15):2511‑2525. doi:10.1517/14656560903160671.; Jaffe GJ, McCallum RM, Branchaud B, Skalak C, Butuner Z, Ashton P. Long‑term follow‑up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology. 2005 Jul;112(7):1192‑8.; Foster S. Uveitis—Current Standard of Care. US Ophthalmic Review. 2007;02:16. doi:10.17925/usor.2007.02.00.16.; Theresa Larson, MD, Robert B. Nussenblatt, MD, MPH, and H. Nida Sen. Emerging Drugs for Uveitis. Expert Opin Emerg Drugs. 2011 June; 16(2):309–322. doi:10.1517/14728214.2011.537824; Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, Nussenblatt RB, Stiehm ER, Tessler H, Van Gelder RN, Whitcup SM, Yocum D. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000 Oct;130(4):492‑513.; W. Benton Boone, MD, and Lewis Slater, MD Immunosuppressive Therapy of Ocular Disease Journal of the national medical association. 1979;71(9):564‑573; Ermakova N. A. [Clinic, diagnostics, etiopathogenesis and treatment of ocular manifestations of Behcet's disease]. Klinika, diagnostika, etiopatogenez i lechenie glaznykh proyavleniy bolezni Bekhcheta. [Clinical ophthalmology]. Klinicheskaya oftal'mologiya. 2002;3(1):12‑15. (in Russ.).; Tamesis RR, Rodriguez A, Christen WG, Akova YA, Messmer E, Foster CS. Systemic drug toxicity trends in immunosuppressive therapy of immune and inflammatory ocular disease. Ophthalmology. 1996 May;103(5):768‑775.; Mirshahi A, Hoehn R., Lorenz K, Kramann Ch., Holger Baatz. Anti‑Tumor Necrosis Factor Alpha for Retinal Diseases: Current Knowledge and Future Concepts. J Ophthalmic Vis Res 2012;7 (1):39‑44.; Newell R. Washburn et al Polymer conjugated inhibitors of tumor necrosis factor‑α for local control of inflammation. Biomatter. 2013;3:3.; Yu He. New options for uveitis treatment. Int J Ophtalmol 2013;6(5):702‑707. doi:10.3980/j.issn.2222‑3959.2013.; Santos Lacomba M, Marcos Martín C, Gallardo Galera JM, Gómez Vidal MA, Collantes Estévez E, Ramírez Chamond R, Omar M. Aqueous humor and serum tumor necrosis factor‑alpha in clinical uveitis. Ophthalmic Res. 2001 Sep‑Oct;33(5):251‑255.; Sánchez‑Cano D, Callejas‑Rubio J, Ruiz‑Villaverde R, Ríos‑Fernández R, Ortego‑Centeno N. Off‑Label Uses of Anti‑TNF Therapy in Three Frequent Disorders: Behçet’s Disease, Sarcoidosis, and Noninfectious Uveitis. Mediators of Inflammation. 2013;2013:1‑10. doi:10.1155/2013/286857.; E W Lindstedt, G S Baarsma, R W A M Kuijpers, P M van Hagen Anti‑TNF‑a therapy for sight threatening uveitis Br J Ophthalmol 2005;89:533–536. doi:10.1136/bjo.2003.037192; Weiss K, Steinbrugger I, Weger M, et al. Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab. Eye (Lond) 2009;23(9):1812–1818. doi:10.1038/eye.2008.388.; Mackensen F, Heinz C, Becker MD, Heiligenhaus A. Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Retina. 2008;28(1):41–45. doi:10.1097/IAE.0b013e318156db75.; Acharya NR, Hong KC, Lee SM. Ranibizumab for refractory uveitis‑related macular edema. Am J Ophthalmol. 2009;148(2):303–309. doi:10.1016/j.ajo.2009.03.028.; Voinov V.A. [Efferent therapy. Membrane plasmapheresis]. M., OAO «Novosti»; 2010. (in Russ.).; Yu X, Ma J, Tian J, Jiang S, Xu P, Han H, Wang L. A controlled study of double filtration plasmapheresis in the treatment of active rheumatoid arthritis. J Clin Rheumatol. 2007Aug;13(4):193‑198. doi:10.1097/RHU.0b013e318124a483.; Yu X, Wang L, Xu P, Lu W, Lan G, Ping L, Wang X, Tian J, Liu J.Effects of double filtration plasmapheresis, leflunomide, and methotrexate on inflammatory changes found through magnetic resonance imaging in early rheumatoid arthritis. J Rheumatol.2012 Jun;39(6):1171‑1178. doi:10.3899/jrheum.110978.; Pepper RJ, Chanouzas D, Tarzi R, et al. Intravenous Cyclophosphamide and Plasmapheresis in Dialysis‑Dependent ANCA‑Associated Vasculitis. Clinical Journal of the American Society of Nephrology : CJASN. 2013;8(2):219‑224. doi:10.2215/CJN.03680412.; Muangchan C, van Vollenhoven RF, Bernatsky SR, Smith CD, Hudson M, Inanç M, Rothfield NF, Nash PT, Furie RA, Senécal JL, Chandran V, Burgos‑Vargas R, Ramsey‑Goldman R, Pope JE. Treatment Algorithms in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2015 Sep;67(9):1237‑45. doi:10.1002/acr.22589.; Cardenas‑Garcia J., D Farmakiotis, B Baldovino , P Kim. Wegener’s granulomatosis in a middle‑aged woman presenting with dyspnea, rash, hemoptysis and recurrent eye complaints: a case report. Journal of Medical Case Reports 2012;6:335. DOI:10.1186/1752‑1947‑6‑335; Frolov A.B. [The use of extracorporeal hemocorrection based on plasmapheresis in the treatment of endogenous uveitis and autoimmune eye diseases]. Primenenie ekstrakorporal'noy gemokorrektsii na osnove plazmafereza pri lechenii endogennykh uveitov i autoimmunnykh zabolevaniy glaz. [Annals of Ophthalmology]. Vestnik oftal'mologii. 2009; 125(5):57‑60. (in Russ.).; Chernyshjova A.D. [The use of ozone and plasmapheresis in treatment of uveitis]. Primenenie ozona i plazmafereza v kompleksnom lechenii uveitov. Primenenie ozona i plazmafereza v kompleksnom lechenii uveitov. [Bulletin of the Siberian medicine]. Byulleten' sibirskoy meditsiny. 2009;3:117121. (in Russ.).; Rjabceva A.A. [Effect of exchange plasmapheresis hydroand hemodynamics and functional eye indices during uveitis]. Vlijanie obmennogo plazmafereza na gidro‑i gemodinamiku i funkcional'nye pokazateli glaza pri uveitah. [Ophthalmology Journal]. Oftal'mologicheskij Zhurnal. 1999;6:361‑365. (in Russ.).; Grechanyi M.P., Chentsova O.B., Kildushevskii A.V, Tret’yak E.B. [Prospects for the use of extracorporeal blood correction in the treatment of autoimmune diseases of the eye]. Perspektivy ispol'zovaniya ekstrakorporal'noy gemokorrektsii v lechenii autoimmunnykh zabolevaniy glaz. [Russian Medical Journal. Clinical Ophthalmology]. Rossiyskiy meditsinskiy zhurnal. Klinicheskaya oftal'mologiya. 2006;3:115‑119 (in Russ.).; Razumova I.Ju., Safonova T.N., Komov V.V., Fedorov A.A. [Extracorporeal treatment of certain autoimmune diseases of the eye]. Jekstrakorporal'nye metody lechenija nekotoryh autoimmunnyh zabolevanij glaz. [Annals of ophthalmology]. Vestnik oftal'mologii. 2010;3:21‑25. (in Russ.).; Onishhenko A.L. [Exchange plasmapheresis with ozonation cell mass in the treatment of endogenous uveitis]. Obmennyj plazmaferez s ozonirovaniem kletochnoj massy pri lechenii jendogennyh uveitov. [Annals of ophthalmology]. Vestnik oftal'mologii. 2011;127(6):33‑35. (in Russ.).; Kopaeva V.G. [Eye diseases. Fundamentals of Ophthalmology]. M.:Meditsina; 2012. (In Russ); https://www.ophthalmojournal.com/opht/article/view/371
-
11Report
Θεματικοί όροι: vitiligo, state register of medicines, content analysis, глюкокортикоиды, glucocorticoids, государственный реестр лекарственных средств, фотосенсибилизаторы, photosensitizers, контент-анализ, 3. Good health, комбинированный препарат, antioxidants, иммуносупрессанты, immunosuppressants, витилиго, антиоксиданты, combined drug
-
12Academic Journal
Συγγραφείς: T. A. Panafidina, Т. А. Панафидина
Πηγή: Rheumatology Science and Practice; Vol 52, No 2 (2014); 230-237 ; Научно-практическая ревматология; Vol 52, No 2 (2014); 230-237 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20142
Θεματικοί όροι: иммуносупрессанты, systemic lupus erythematosus, lesion of the nervous system in systemic lupus erythematosus, lupus nephritis, pregnancy in systemic lupus erythematosus, glucocorticoids, immuno- suppressants, системная красная волчанка, поражение нервной системы при системной красной волчанке, волчаночный нефрит, беременность при системной красной вол- чанке, глюкокортикоиды
Περιγραφή αρχείου: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/1931/1202; Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommen- dations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010 Dec;69(12):2074–82. DOI:10.1136/ard.2010.130476.; Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–7. DOI: http://dx.doi.org/10.1002/art.1780251101; The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999 Apr;42(4):599–608. DOI: http://dx.doi.org/10.1002/1529- 0131(199904)42:43.0.CO;2-F.; Petri M, Orbai AM, Alarcоn GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classifi- cation criteria for systemic lupus erythematosus. Arthritis Rheum. 2012 Aug;64(8):2677–86. DOI:10.1002/art.34473.; Popescu A, Kao AH. Neuropsychiatric systemic lupus erythemato- sus. Curr Neuropharmacol. 2011 Sep;9(3):449–57. DOI:10.2174/157015911796557984.; Unterman A, Nolte JE, Boaz M, et al. Neuropsychiatric syn- dromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum. 2011 Aug;41(1):1–11. DOI:10.1016/j.semarthrit.2010.08.001.; Bertsias GK, Boumpas DT. Pathogenesis, diagnosis and manage- ment of neuropsychiatric SLE manifestations. Nat Rev Rheumatol. 2010 Jun;6(6):358–67. DOI:10.1038/nrrheum.2010.62. Epub 2010 May 11.; Govoni M. The clinical picture of neuropsychiatric lupus: chal- lenges and critical issues. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy; 2013.; Luyendijk J, Steens SC, Ouwendijk WJ, et al. Neuropsychiatric systemic lupus erythematosus: lessons learned from magnetic reso- nance imaging. Arthritis Rheum. 2011 Mar;63(3):722–32. DOI:10.1002/art.30157.; Meroni PL. Pathogenesis of CNS involvment in SLE. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy; 2013.; Bertsias G. EULAR recommendations for neuropsychiatric lupus: pitfalls and challenges. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy; 2013.; Boumpas DT. EULAR recommendations for lupus nephritis: bal- ancing efficacy vs toxicity, pitfalls, and challenges. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy; 2013.; Houssiau FA. Treatment of lupus nephritis: old and new approaches. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy; 2013.; Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association- European Dialysis and Transplant Association (EULAR/ERA- EDTA) recommendations for the management of adult and paedi- atric lupus nephritis. Ann Rheum Dis. 2012 Nov;71(11):1771–82. DOI:10.1136/annrheumdis-2012-201940. Epub 2012 Jul 31.; Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and man- agement of lupus nephritis. Arthritis Care Res (Hoboken). 2012 Jun;64(6):797–808. DOI:10.1002/acr.21664.; Moroni G. Clinical and laboratory features of lupus nephritis and prognostic factors. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy; 2013.; Bijlsma JWJ. Glucocorticoids in SLE: principles of therapy and monitoring. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy; 2013.; Costedoat-Chalumeau N. Hydroxychloroquine adherence to treatment and SLE. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE; Pisa, Italy. 2013.; Ruiz-Irastorza G. Traditional drugs in SLEfocus on immunosup- pressive drugs. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy. 2013.; Thamer M, Hernan MA, Zhang Y. Prednisone, lupus activity, and permanent organ damage. J Rheumatol. 2009 Mar;36(3):560–4. DOI:10.3899/jrheum.080828.; Houssiau FA, Isenberg D. Towards treating lupus nephritis without oral steroids: a dream-come-true? Ann Rheum Dis. 2013 Aug;72(8):1271–2. DOI:10.1136/annrheumdis-2013-203205.; Ding HJ, Gordon C. New biologic therapy for systemic lupus ery- thematosus. Curr Opin Pharmacol. 2013 Jun;13(3):405–12. DOI:10.1016/j.coph.2013.04.005.; Mosca M. When to use biologic therapies in clinical practice. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy; 2013.; Rovin BH, Furie R, Latinis K, et al; LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012 Apr;64(4):1215–26. DOI:10.1002/art.34359.; Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythe- matosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010 Jan;62(1):222–33. DOI:10.1002/art.27233.; Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013 Aug;72(8):1280–6. DOI:10.1136/annrheumdis-2012-202844.; Halpern WG, Lappin P, Zanardi T, et al. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: Pharmacokinetic, pharmacodynamic and toxicologic effects. Toxicol Sci. 2006 Jun;91(2):586–99. DOI: http://dx.doi.org/10.1093/toxsci/kfj148.; Baker KP, Edwards BM, Main SH, et al. Generation and char- acterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003;48(11):3253–65.; Navarra SV, Guzman RM, Gallacher AE, et al.; BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-con- trolled, phase 3 trial. Lancet. 2011 Feb 26;377(9767):721–31. DOI:10.1016/S0140-6736(10)61354-2.; Furie R, Petri M, Zamani O, et al.; BLISS-76 Study Group.; A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011 Dec;63(12):3918–30. DOI:10.1002/art.30613.; Aringer M, Houssiau F, Gordon C, et al. Adverse events and effi-; cacy of TNF-alpha blockade with infliximab in patients with sys- temic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford). 2009 Nov;48(11):1451–4. DOI:10.1093/rheumatology/kep270.; Merrill JT, Burgos-Vargas R, Westhovens R. The efficacy and safe- ty of abatacept in patients with non-life-threatening manifesta- tions of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010 Oct;62(10):3077–87. DOI:10.1002/art.27601.; Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010 Feb;62(2):542–52. DOI:10.1002/art.27221.; Khamashta M. Therapeutic algorithms for active SLE in pregnan- cy. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy. 2013.; Ruiz-Irastorza G, Khamashta M, Hughes GR. Does SLE flare during pregnancy? Scand J Rheumatol Suppl. 1998;107:76–9.; Оstensen M. Drug therapy and toxicity in pregnancy and lacta- tion. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy; 2013.; Brucato A. Neonatal lupus. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy; 2013.; Ruiz-Irastorza G, Khamashta MA. Lupus and pregnancy: inte- grating clues from the bench and bedside. Eur J Clin Invest. 2011 Jun;41(6):672–8. DOI:10.1111/j.1365-2362.2010.02443.x.; Sammaritano LR. Therapy insight: guidelines for selection of con- traception in women with rheumatic diseases. Nat Clin Pract Rheumatol. 2007 May;3(5):273–81; quiz 305–6. DOI: http://dx.doi.org/10.1038/ncprheum0484.; Tincani A. Contraception, prevention of infertility and hormonal therapies in SLE. Proceedings of the 6th EULAR Scientifically Endorsed Course on SLE. Pisa, Italy; 2013.; Buyon JP, Petri MA, Kim MY, et al. The effect of combined estro- gen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005 Jun 21;142(12 Pt 1):953–62. DOI: http://dx.doi.org/10.7326/0003-4819-142-12_Part_1-200506210- 00004.; Sanchez-Guerrero J, Gonzalez-Perez M, Durand-Carbajal M, et al. Menopause hormonal therapy in women with systemic lupus erythematosus. Arthritis Rheum. 2007 Sep;56(9):3070–9. DOI: http://dx.doi.org/10.1002/art.22855.; Moyer VA; U.S. Preventive Services Task Force. Menopausal hor- mone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013 Jan 1;158(1):47–54. DOI: http://dx.doi.org/10.7326/0003-4819-158-1-201301010-00553.
-
13Academic Journal
Συγγραφείς: Панафидина, Татьяна
Θεματικοί όροι: VI НАУЧНО-ОБРАЗОВАТЕЛЬНЫЙ КУРС EULAR, СИСТЕМНАЯ КРАСНАЯ ВОЛЧАНКА, ПОРАЖЕНИЕ НЕРВНОЙ СИСТЕМЫ ПРИ СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКЕ, ВОЛЧАНОЧНЫЙ НЕФРИТ, БЕРЕМЕННОСТЬ ПРИ СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКЕ, ГЛЮКОКОРТИКОИДЫ, ИММУНОСУПРЕССАНТЫ
Περιγραφή αρχείου: text/html
-
14Academic Journal
Συγγραφείς: Кондратьева, Н., Рассказов, Я., Бакулев, А.
Θεματικοί όροι: ПСОРИАЗ, ФОТОТЕРАПИЯ, ЦИТОСТАТИКИ, ИММУНОСУПРЕССАНТЫ, БИОЛОГИЧЕСКИЕ ПРЕПАРАТЫ
Περιγραφή αρχείου: text/html
-
15Academic Journal
Συγγραφείς: Карташева, В.
Θεματικοί όροι: РЕВМАТИЧЕСКИЕ ЗАБОЛЕВАНИЯ У ДЕГЕЙ, ИММУНОСУПРЕССАНТЫ, ПЛАЗМАФЕРЕЗ, ГИПОТЕНЗИВНЫЕ, ВАЗОДИЛАТАТОРЫ, МИОГЛОБИНУРИЯ
Περιγραφή αρχείου: text/html
-
16Academic Journal
Πηγή: Научно-практическая ревматология.
Θεματικοί όροι: VI НАУЧНО-ОБРАЗОВАТЕЛЬНЫЙ КУРС EULAR, СИСТЕМНАЯ КРАСНАЯ ВОЛЧАНКА, ПОРАЖЕНИЕ НЕРВНОЙ СИСТЕМЫ ПРИ СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКЕ, ВОЛЧАНОЧНЫЙ НЕФРИТ, БЕРЕМЕННОСТЬ ПРИ СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКЕ, ГЛЮКОКОРТИКОИДЫ, ИММУНОСУПРЕССАНТЫ, 3. Good health
Περιγραφή αρχείου: text/html
-
17Academic Journal
Πηγή: Практическая медицина.
Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, ПСОРИАЗ, ФОТОТЕРАПИЯ, ЦИТОСТАТИКИ, ИММУНОСУПРЕССАНТЫ, БИОЛОГИЧЕСКИЕ ПРЕПАРАТЫ, 3. Good health
Περιγραφή αρχείου: text/html
-
18Academic Journal
Πηγή: Вопросы современной педиатрии.
Θεματικοί όροι: РЕВМАТИЧЕСКИЕ ЗАБОЛЕВАНИЯ У ДЕГЕЙ, ИММУНОСУПРЕССАНТЫ, ПЛАЗМАФЕРЕЗ, ГИПОТЕНЗИВНЫЕ, ВАЗОДИЛАТАТОРЫ, МИОГЛОБИНУРИЯ, 3. Good health
Περιγραφή αρχείου: text/html
